Spaulding Clinical's Innovations Produce Best Quality in 240 Subject TQT Study

West Bend, WI, November 2, 2009 - Spaulding Clinical Research, a newly designed Phase I Unit provisioned for all types of pharmaceutical trials including the most complex cardiac safety studies, announces the recent completion of an 11-week, 240 subject thorough QT study (TQT). Results were available for 99.63% of the total 17,280 ECGs required for the study in real time throughout the study, and there was no ECG data loss, 99.85% of pre- scheduled ECGs being successfully captured with high quality.

Chéri Barta Joins Spaulding Clinical

West Bend, WI, November 2, 2009 - Spaulding Clinical Research, a newly designed Phase I Unit provisioned for all types of pharmaceutical trials including the most complex cardiac safety studies, announces that Ms. Chéri Barta has joined as the Senior Director, Core ECG Lab Services.

$2.2 Million Award Announcement

Spaulding Clinical Announces $2.2 Million Program Award

West Bend, WI, March 9, 2009 - Spaulding Clinical Research, LLC a leading provider of Phase I and Cardiac Core Lab services has announced the award of a 240 subject, Thorough QT (TQT) study by a major European pharmaceutical company.